- Home
- NML vs BBIO Comparison
NML vs BBIO Comparison
Compare NML & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NML
- BBIO
- Stock Information
- Founded
- NML 2012
- BBIO 2015
- Country
- NML United States
- BBIO United States
- Employees
- NML N/A
- BBIO N/A
- Industry
- NML Finance/Investors Services
- BBIO Biotechnology: Pharmaceutical Preparations
- Sector
- NML Finance
- BBIO Health Care
- Exchange
- NML Nasdaq
- BBIO Nasdaq
- Market Cap
- NML 454.4M
- BBIO 6.7B
- IPO Year
- NML N/A
- BBIO 2019
- Fundamental
- Price
- NML $8.38
- BBIO $34.83
- Analyst Decision
- NML
- BBIO Strong Buy
- Analyst Count
- NML 0
- BBIO 12
- Target Price
- NML N/A
- BBIO $57.09
- AVG Volume (30 Days)
- NML 219.3K
- BBIO 3.2M
- Earning Date
- NML 01-01-0001
- BBIO 04-29-2025
- Dividend Yield
- NML 9.75%
- BBIO N/A
- EPS Growth
- NML N/A
- BBIO N/A
- EPS
- NML N/A
- BBIO N/A
- Revenue
- NML N/A
- BBIO $127,415,000.00
- Revenue This Year
- NML N/A
- BBIO $13.67
- Revenue Next Year
- NML N/A
- BBIO $118.02
- P/E Ratio
- NML N/A
- BBIO N/A
- Revenue Growth
- NML N/A
- BBIO N/A
- 52 Week Low
- NML $6.09
- BBIO $21.62
- 52 Week High
- NML $7.33
- BBIO $39.47
- Technical
- Relative Strength Index (RSI)
- NML 49.52
- BBIO 46.94
- Support Level
- NML $8.20
- BBIO $36.85
- Resistance Level
- NML $8.54
- BBIO $39.16
- Average True Range (ATR)
- NML 0.22
- BBIO 1.47
- MACD
- NML 0.03
- BBIO -0.07
- Stochastic Oscillator
- NML 64.79
- BBIO 25.61
About NML Neuberger Berman Energy Infrastructure and Income Fund Inc.
Neuberger Berman Energy Infrastructure & Income Fund Inc is a closed-end investment management company based in the United States. Invest in Capital Markets, Chemicals, Oil, Gas & Consumable Fuels, Electric Utilities, Independent Power and Renewable Electricity Producers, Multi Utilities. Maximum is done in Oil, Gas & Consumable Fuels.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.